{'fraction_non_alphanumeric': 0.02072538860103627, 'fraction_numerical': 0.0069084628670120895, 'mean_word_length': 5.660919540229885, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1

Recent studies have demonstrated the presence of circulating MelanA (MART1)‐specific cytotoxic T lymphocytes in a significant number of vitiligo patients when compared to control subjects. High levels of the skin‐homing receptor cutaneous lymphocyte‐associated antigen were expressed on the T cells and their frequency correlated with the extent of depigmentation and disease activity in the vitiligo patients. The present study was designed to examine vitiligo patient sera for the presence of autoantibodies to MelanA. The incidence of autoantibodies to MelanA in patients with vitiligo (n = 51) and in healthy individuals (n = 20) was examined using a radiobinding assay with 35S]‐labelled MelanA and using Western blot analysis with a glutathione S‐transferase (GST)‐MelanA fusion protein. Autoantibodies to MelanA could not be detected in any of the vitiligo patient sera or control sera analysed using either of these detection systems. It is therefore possible that MelanA only induces cellular rather than humoral autoreactivity in vitiligo.